Epidemiology of hepatitis C virus infection in HIV-infected individuals

Journal of Viral Hepatitis

Volumn 15, Issue 11, 2008, Pages 773-781

  Thomson, Emma C ^a   Main, Janice ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Epidemiology; HCV; HIV

Indexed keywords

ABACAVIR; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ERYTHROPOIETIN; INTERFERON; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANEMIA; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DISEASE COURSE; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; LACTIC ACIDOSIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; SEXUAL TRANSMISSION; SIDE EFFECT; VIRUS TRANSMISSION; WEIGHT REDUCTION;

COMORBIDITY; DISEASE PROGRESSION; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 54849434221     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00981.x     Document Type: Review

References (72)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006 44 (Suppl. 1 S6 S9.
2. Quaranta JF, Delaney SR, Alleman S, Cassuto JP, Dellamonica P, Allain JP. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J Med Virol 1994 42 : 29 32.
3. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001 32 : 492 497.
4. Arnold DM, Julian JA, Walker IR, Association of Hemophilia Clinic Directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006 108 : 460 464.
5. Pillonel J, Saura C, Courouce AM. Screening of viral markers for HIV HBV and HCV infections in blood donors in France and residual risk of viral transmission by blood transfusion. Euro Surveill 1998 3 : 76 79.
6. WHO Global Database on Blood Safety 2001-2002.
7. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999 77 : 801 807.
8. Karuru JW, Lule GN, Joshi M, Anzala O. Prevalence of HCV and HCV/HIV co-infection among in-patients at the Kenyatta National Hospital. East Afr Med J 2005 82 : 170 172.
9. Agwale SM, Tanimoto L, Womack C et al. Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. Journal of Clinical Virology 2004 31 (Suppl. 1 S3 S6.
10. Ayele W, Nokes DJ, Abebe A et al. Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. J Med Virol 2002 68 : 12 17.
11. Frank C, Mohamed MK, Strickland GT et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000 355 : 887 891.
12. Yerly S, Quadri R, Negro F et al. Nosocomial outbreak of multiple bloodborne viral infections. J Infect Dis 2001 184 : 369 372.
13. de Oliveira T, Pybus OG, Rambaut A et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature, 2006 444 : 836 837.
14. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002 34 : 831 837.
15. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr 2003 33 : 356 364.
16. Mendel I, Clotteau L, Lambert S, Buffet-Janvresse C. Hepatitis C virus infection in an HIV-positive population in Normandy: antibodies, HCV RNA and genotype prevalence. J Med Virol 1995 47 : 231 236.
17. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005 192 (6 992 1002.
18. Rauch A, Rickenbach M, Weber R et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005 41 : 395 402.
19. Quaglio G, Lugoboni F, Pajusco B et al. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis 2003 37 : 33 40.
20. Muga R, Sanvisens A, Bolao F et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001. Drug Alcohol Depend 2006 82 (Suppl. 1 S29 S33.
21. Leruez-Ville M, Kunstmann JM, De Almeida M, Rouzioux C, Chaix ML. Detection of hepatitis C virus in the semen of infected men. Lancet 2000 356 : 42 43.
22. Cohen DE, Russell CJ, Golub SA, Mayer KH. Prevalence of hepatitis C virus infection among men who have sex with men at a Boston community health center and its association with markers of high-risk behavior. AIDS Patient Care STDs 2006 20 : 557 564.
23. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005 40 (1 41 46.
24. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005 12 (2 207 211.
25. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006 20 (8 1157 1161.
26. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007 196 (2 230 238.
27. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007 21 (8 983 991.
28. Vandelli C, Renzo F, Romano L et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004 99 : 855 859.
29. D'Oliveira Jr. A, Voirin N, Allard R et al. Prevalence and sexual risk of hepatitis C virus infection when human immunodeficiency virus was acquired through sexual intercourse among patients of the Lyon University Hospitals, France, 1992-2002. J Viral Hepat 2005 12 : 330 332.
30. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991 115 (10 764 768.
31. Herring BL, Page-Shafer K, Tobler LH, Delwart EL. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 2004 190 : 1396 1403.
32. Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989 97 : 1559 1561.
33. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991 115 : 764 768.
34. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994 87 : 555 561.
35. Sanchez-Quijano A, Andreu J, Gavilan F et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995 14 : 949 953.
36. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (Baltimore, Md.) 1999 30 : 1054 1058.
37. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006 42 : 262 270.
38. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003 362 : 1708 1713.
39. Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006 44 : 47 55.
40. Rosenberg PM, Farrell JJ, Abraczinskas DR, Graeme-Cook FM, Dienstag JL, Chung RT. Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection. Am J Gastroenterol 2002 97 : 478 483.
41. Katzenstein DA, Hammer SM, Hughes MD et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996 335 : 1091 1098.
42. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000 356 : 1800 1805.
43. Wright TL, Hollander H, Pu X et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology (Baltimore, Md.), 1994 20 : 1152 1155.
44. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995 172 : 1503 1508.
45. Dorrucci M, Valdarchi C, Suligoi B et al. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS (London, England) 2004 18 : 2313 2318.
46. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D. Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection. Lancet 1993 341 : 958 959.
47. Soriano V, Garcia-Samaniego J, Bravo R et al. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group. J Infect 1995 31 : 9 13.
48. Pesce A, Taillan B, Rosenthal E et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993 341 : 1597.
49. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004 292 : 2839 2848.
50. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004 351 : 451 459.
51. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 : 438 450.
52. Mauss S, Valenti W, DePamphilis J et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS (London, England) 2004 18 : F21 F25.
53. Hadziyannis SJ, Sette Jr. H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
54. Ramos B, Nunez M, Rendon A et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 2007 14 : 387 391.
55. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS (London, England) 2004 18 : F27 F36.
56. Perez-Olmeda M, Soriano V, Asensi V et al. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res Hum Retroviruses 2003 19 : 1083 1089.
57. Lissen E, Clumeck N, Sola R et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS (London, England) 2006 20 : 2175 2181.
58. Bani-Sadr F, Lapidus N, Melchior JC et al. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepat 2008 15 (4 255 260.
59. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (Baltimore, Md.), 2002 35 : 182 189.
60. Mehta SH, Thomas DL, Torbenson M et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology (Baltimore, Md.), 2005 41 : 123 131.
61. Barreiro P, Rodriguez-Novoa S, Labarga P et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007 195 : 973 979.
62. Tural C, Fuster D, Tor J et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003 10 : 118 125.
63. Bani-Sadr F, Carrat F, Rosenthal E et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005 41 : 1806 1809.
64. Bani-Sadr F, Denoeud L, Morand P et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007 45 (1 123 125.
65. Labarga P, Soriano V, Vispo ME et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007 196 : 670 676.
66. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001 345 : 1452 1457.
67. Serpaggi J, Chaix ML, Batisse D et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS (London, England) 2006 20 : 233 240.
68. Netski DM, Mosbruger T, Astemborski J, Mehta SH, Thomas DL, Cox AL. CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis 2007 195 : 857 863.
69. Stramer SL, Glynn SA, Kleinman SH et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351 : 760 768.
70. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003 36 : 97 100.
71. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P, The Manhattan HIV Brain Bank. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004 62 : 957 962.
72. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994 21 : 241 243.